Profile: United Therapeutics Corp (UTHR.O)
24 Feb 2017
United Therapeutics Corporation, incorporated on June 26, 1996, is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company's therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb). The Company is engaged in early-stage research and development into a range of organ transplantation-related technologies. It is also engaged in a range of research and development activities in xenotransplantation, regenerative medicine and ex-vivo lung perfusion, all of which are intended to supply transplantable organs and tissues. These activities are focused on lungs, but are also being applied to other organs, such as hearts and kidneys.
The Company's Prostacyclin analogues are stable synthetic forms of prostacyclin. The Company's lead product is Remodulin (treprostinil) Injection (Remodulin), which is administered subcutaneously (under the skin) or intravenously (in the vein) for the treatment of pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise. The United States Food and Drug Administration (FDA) approved Remodulin for subcutaneous and intravenous administration. Outside the United States, Remodulin is approved in over 40 countries. It is developing technologies to make Remodulin delivery, such as implantable pump systems for intravenous Remodulin and pre-filled, semi-disposable pumps for subcutaneous Remodulin. It sells Remodulin to specialty pharmaceutical distributors in the United States and to pharmaceutical distributors internationally.
The FDA has approved Tyvaso (treprostinil) Inhalation Solution (Tyvaso), an inhaled prostacyclin therapy for the treatment of PAH. The FDA has approved Orenitram (treprostinil) Extended-Release Tablets (Orenitram), an oral prostacyclin analogue for the treatment of PAH. Its subsidiary, Lung Biotechnology PBC, is developing another oral prostacyclin analogue for the treatment of PAH called esuberaprost.
Phosphodiesterase Type 5 (PDE-5) Inhibitor
The Company's PDE-5 inhibitors act to inhibit the degradation of cyclic guanosine monophosphate (cyclic GMP) in cells. Cyclic GMP is activated by nitric oxide (NO), a naturally occurring substance in the body that mediates the relaxation of vascular smooth muscle. Its PDE-5 inhibitor is Adcirca (tadalafil) tablets (Adcirca), a once-daily oral therapy for the treatment of PAH. The FDA has approved Adcirca for the treatment of PAH.
The Company's MAbs are antibodies that bind to cancerous tumors and destroy the cancer cells through a mechanism called antibody-dependent cell mediated cytotoxicity. The FDA has approved Unituxin (dinutuximab) Injection (Unituxin), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with neuroblastoma achieving at least a partial response to prior first-line multiagent, multimodality therapy.
The Company competes with Watson Laboratories, Inc., SteadyMed Ltd., Actavis Laboratories FL, Inc., Pfizer, Inc., GlaxoSmithKline PLC, Teva Pharmaceuticals USA, Inc., Actelion Pharmaceuticals Ltd, Bayer Schering Pharma AG, Gilead, Nippon Shinyaku Co., Ltd. and Arena Pharmaceuticals, Inc.
United Therapeutics Corp
1040 SPRING ST
SILVER SPRING MD 20910